Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 14/20 | 0.42 |
| ▸ | CDK9 | P50750 | 14/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094340 | 0.84 | TRPV1 (0.45) | QDPRCCNT1CDK9 | |
| SCHEMBL20993990 | 0.84 | MAPT (0.50) | QDPRCCNT1CDK9ALOX15MAPT | |
| SCHEMBL5511829 | 0.83 | QDPR (0.43) | QDPRPOLBMAPT | |
| SCHEMBL5511826 | 0.83 | QDPR (0.43) | QDPRPOLBMAPT | |
| SCHEMBL21714595 | 0.81 | MAPT (0.44) | QDPRPOLBALOX15MAPT | |
| SCHEMBL5386097 | 0.80 | QDPR (0.65) | QDPRPOLBALOX15 | |
| SCHEMBL22324848 | 0.77 | QDPR (0.58) | QDPRCCNT1CDK9POLBALOX15 | |
| SCHEMBL16874745 | 0.77 | QDPR (0.58) | QDPRCCNT1CDK9POLBALOX15 | |
| SCHEMBL5460061 | 0.77 | MAPT (0.60) | QDPRPOLBMAPT | |
| SCHEMBL28727024 | 0.76 | MAPT (0.44) | QDPRCCNT1CDK9POLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | QDPR 873/4885CCNT1 3131/4885CDK9 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.